Two researchers at the University of Houston say that recent work highlights the promise of liver X receptors, or LXRs, as a target for hard-to-treat cases of pancreatic cancer. Cancer biologist Chin-Yo Lin, an assistant professor with the UH Center for Nuclear Receptors and Cell Signaling, says there is now enough evidence to demonstrate that LXRs are a promising field for a variety of malignancies. "Our findings point to a class of receptors that can be precisely targeted by drug compounds and are expected to stimulate both basic and translational research on their functions and application as a drug target," Lin said. "Long-term goals are to develop additional drug compounds and clinical testing in human subjects, which will require several more years of research." Release